UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of May 2018
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: May 23, 2018 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure Reports Financial Results for Quarter Ended
March 31, 2018
WINNIPEG, May 23, 2018 /CNW/ - Medicure Inc. ("Medicure"
or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from
operations for the quarter ended March 31, 2018.
Quarter Ended March 31, 2018 Highlights:
| · | Recorded net revenue from the sale of AGGRASTAT®
(tirofiban hydrochloride) of $6.1 million during the quarter ended March 31, 2018 compared to $7.0 million for the quarter ended
March 31, 2017; |
| · | Adjusted earnings before interest, taxes, depreciation
and amortization (EBITDA1) for the quarter ended March 31, 2018 was $874,000 compared to adjusted EBITDA of $1.7 million
for the quarter ended March 31, 2017; and |
| · | Net income for the quarter ended March 31, 2018 was
$1.4 million compared to a net loss of $5.1 million for the quarter ended March 31, 2017. |
| · | $72.4 million in cash and short-term investments as
at March 31, 2018. |
Financial Results
Net revenues from AGGRASTAT® for the three
months ended March 31, 2018 were $6.1 million compared to $7.0 million for the three months ended March 31, 2017.
The Company continues to experience an increase in patient
market share held by the product and an increase in the number of new hospital customers using AGGRASTAT® leading
to the highest hospital demand for AGGRASTAT® in the Company's history. Although, there was an increase in use of
AGGRASTAT®, the lower net revenue was largely due to a stronger Canadian dollar compared to its US counterpart and
increased competitive pricing of generic Integrilin.
Medicure continues to focus on expanding the customer base
for AGGRASTAT®. Along with this, the Company has begun to diversify revenues with the recent launch of ZYPITAMAGTM
(pitavastatin magnesium), its second cardiovascular drug targeting the US market. Additional drugs are expected to be launched
in the next 12 to 15 months.
Adjusted EBITDA for the three months ended March 31, 2018
was $874,000 compared to $1.7 million for the three months ended March 31, 2017. The decrease in adjusted EBITDA for the quarter
is the result of:
| · | lower revenues which were primarily due to lower discounted
prices for AGGRASTAT® and a higher Canadian dollar relative to its US counterpart, |
| · | higher cost of goods sold due to higher volume of
AGGRASTAT® sold during the period, |
partially offset by;
| · | lower research and development expenses when compared
to the same period in 2017 as a result of timing of expenses relating to the Company's research and development projects. |
Net income for the three months ended March 31, 2018 was $1.4
million or $0.09 per share compared to a net loss of $5.1 million or $0.32 per share for the three months ended March 31, 2017,
however the net loss for the 2017 quarter includes a net loss of $6.3 million from discontinued operations relating to the results
from the Apicore business, which was divested in 2017. Excluding the loss from discontinued operations, net income for the
three months ended March 31, 2018 increased by $176,000 over same period in 2017 primarily due to foreign exchange gains resulting
from increased U.S. dollar denominated cash and short-term investment balances, partially offset by lower revenues for the three
months ended March 31, 2018.
As at March 31, 2018, the Company had cash and short-term
investments totaling $72.4 million compared to $5.3 million as of December 31, 2017. This consisted of $14.4 million of unrestricted
cash and $58.0 million of short-term investments in the form of term deposits with maturities of greater than three months and
less than one year. As at March 31, 2018, the Company had working capital of $73.6 million compared to December 31, 2017 of $70.9
million. The Company had cash from operating activities of $319,000 for the three months ended March 31, 2018 compared to cash
used in operating activities of $834,000 for the three months ended March 31, 2017.
All amounts referenced herein are in Canadian dollars unless
otherwise noted.
Notes
(1) The Company defines EBITDA as "earnings
before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted
for non-cash and one-time items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the
quarters ended March 31, 2018 and 2017 results prepared using International Financial Reporting Standards ("IFRS"), do
not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by
other companies.
Conference Call Info:
Topic: Medicure's Q1 2018 Results
Call date: Thursday May 24, 2018
Time: 7:30 AM Central Time (8:30 AM Eastern Time)
Canada toll-free: 1 (888) 465-5079 Canada toll:
1 (416) 216-4169
United States toll-free: 1 (888) 545-0687
Passcode: 5781086#
Webcast: This conference call will be webcast live over
the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors.html
You may request international country-specific access information
by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations
during the question-and-answer period at the end of the conference call. A recording of the call will be available following the
event at the Company's website.
About Medicure
Medicure is a pharmaceutical company focused on the development
and commercialization of therapeutics for the U.S. cardiovascular market. The primary focus of the Company is the marketing and
distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAGTM (pitavastatin magnesium)
tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information
on Medicure please visit www.medicure.com.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
Forward Looking Information: Statements contained in
this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes",
"may", "plans", "will", "estimates", "continues", "anticipates", "intends",
"expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable
Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively
referred to as "forward-looking statements"). Forward-looking statements, include the target launch date for new products,
the estimated number of products the Company will be selling in the future, estimates, analysis and opinions of management of the
Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as
other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements
are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause
the actual results, events or developments to be materially different from any future results, events or developments expressed
or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking
statements. Such risk factors include, among others, the Company's future product revenues, stage of development, additional capital
requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the
Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government
regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number
of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic
conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results;
the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability
of financing for the Company's commercial operations and/or research and development projects, or the availability of financing
on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand
for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company
undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors,
other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to
the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities
or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December
31, 2017.
AGGRASTAT® (tirofiban hydrochloride) is a registered
trademark of Medicure International Inc.
Condensed Consolidated Interim Statements of Financial Position
(expressed in Canadian dollars)
(unaudited) |
|
|
March 31, 2018 |
|
December 31, 2017 |
|
|
|
|
|
Assets |
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
$ |
14,392,250 |
$ |
5,260,480 |
|
Short-term investments |
|
58,023,000 |
|
- |
|
Accounts receivable |
|
7,699,427 |
|
8,588,255 |
|
Consideration receivable |
|
- |
|
82,678,366 |
|
Inventories |
|
2,556,730 |
|
3,075,006 |
|
Prepaid expenses |
|
1,465,774 |
|
903,914 |
|
Assets held for sale |
|
- |
|
14,052,861 |
|
Total current assets |
|
84,137,181 |
|
114,558,882 |
Non-current assets: |
|
|
|
|
|
Property and equipment |
|
294,752 |
|
221,622 |
|
Intangible assets |
|
1,805,160 |
|
1,756,300 |
|
Holdback receivable |
|
12,496,866 |
|
12,068,773 |
|
Deferred tax assets |
|
317,195 |
|
326,108 |
|
Total non-current assets |
|
14,913,973 |
|
14,372,803 |
Total assets |
$ |
99,051,154 |
$ |
128,931,685 |
|
|
|
|
|
Liabilities and Equity |
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable and accrued liabilities |
$ |
6,618,362 |
$ |
10,371,103 |
|
Accrued transaction costs |
|
- |
|
22,360,730 |
|
Current income taxes payable |
|
2,417,790 |
|
2,428,560 |
|
Current portion of royalty obligation |
|
1,510,065 |
|
1,537,202 |
|
Liabilities held for sale |
|
- |
|
6,976,313 |
|
Total current liabilities |
|
10,546,217 |
|
43,673,908 |
Non-current liabilities |
|
|
|
|
|
Royalty obligation |
|
2,979,328 |
|
2,911,810 |
|
License fee payable |
|
515,760 |
|
501,800 |
|
Other long-term liabilities |
|
1,175,267 |
|
1,135,007 |
|
Total non-current liabilities |
|
4,670,355 |
|
4,548,617 |
Total liabilities |
|
15,216,572 |
|
48,222,525 |
Equity: |
|
|
|
|
|
Share capital |
|
126,082,379 |
|
125,733,727 |
|
Warrants |
|
1,948,805 |
|
1,948,805 |
|
Contributed surplus |
|
7,159,926 |
|
6,897,266 |
|
Accumulated other comprehensive income |
|
1,827,950 |
|
673,264 |
|
Deficit |
|
(53,184,478) |
|
(54,543,902) |
Total equity |
|
83,834,582 |
|
80,709,160 |
Commitments and contingencies |
|
|
|
|
Subsequent events |
|
|
|
|
Total liabilities and equity |
$ |
99,051,154 |
$ |
128,931,685 |
Condensed Consolidated Interim Statements of Net Income (loss) and Comprehensive Income (loss)
(expressed in Canadian dollars)
(unaudited) |
Three months ended March 31 |
|
2018 |
|
2017 |
Revenue, net |
|
|
|
|
|
Product sales, net |
$ |
6,064,375 |
$ |
7,013,396 |
Cost of goods sold |
|
789,234 |
|
554,398 |
Gross Profit |
|
5,275,141 |
|
6,458,998 |
|
|
|
|
|
Expenses |
|
|
|
|
|
Selling, general and administrative |
|
3,930,727 |
|
3,521,246 |
|
Research and development |
|
909,347 |
|
1,310,023 |
|
|
4,840,074 |
|
4,831,269 |
Income before the undernoted |
|
435,067 |
|
1,627,729 |
|
|
|
|
|
Other income |
|
|
|
|
|
Revaluation of holdback receivable |
|
83,580 |
|
- |
|
|
83,580 |
|
- |
|
|
|
|
|
Finance costs (income): |
|
|
|
|
|
Finance expense, net |
|
76,222 |
|
317,595 |
|
Foreign exchange gain, net |
|
(1,012,760) |
|
(6,130) |
|
|
(936,538) |
|
311,465 |
Net income before taxes |
$ |
1,455,185 |
$ |
1,316,264 |
Current income tax expense |
|
95,761 |
|
133,255 |
Net income before discontinued operations |
$ |
1,359,424 |
$ |
1,183,009 |
Net loss from discontinued operations, net of tax |
|
- |
|
(6,258,534) |
Net income (loss) |
$ |
1,359,424 |
$ |
(5,075,525) |
Translation adjustment, attributable to: |
|
|
|
|
|
Continuing operations |
|
1,154,686 |
|
(395,074) |
|
Discontinued operations |
|
- |
|
(721,024) |
Comprehensive income (loss) |
$ |
2,514,110 |
$ |
(6,191,623) |
|
|
|
|
|
|
|
|
|
|
Earnings per share from continuing operations: |
|
|
|
Basic |
$ |
0.09 |
$ |
0.08 |
|
Diluted |
$ |
0.08 |
$ |
0.07 |
|
|
|
|
|
Loss per share from discontinued operations: |
|
|
|
|
|
Basic |
$ |
- |
$ |
(0.40) |
|
Diluted |
$ |
- |
$ |
(0.40) |
|
|
|
|
|
Earnings (loss) per share: |
|
|
|
|
|
Basic |
$ |
0.09 |
$ |
(0.32) |
|
Diluted |
$ |
0.08 |
$ |
(0.33) |
Condensed Consolidated Interim Statements of Cash Flows
(expressed in Canadian dollars)
(unaudited) |
For the three months ended March 31 |
|
2018 |
|
2017 |
|
|
|
|
|
Cash (used in) provided by: |
|
|
|
|
Operating activities: |
|
|
|
|
|
Net income from continuing operations for the period |
$ |
1,359,424 |
$ |
1,183,009 |
|
Net loss from discontinued operations for the period |
|
- |
|
(6,258,534) |
|
|
1,359,424 |
|
(5,075,525) |
Adjustments for: |
|
|
|
|
|
Current income tax expense |
|
95,761 |
|
133,255 |
|
Deferred income tax recovery |
|
- |
|
(1,289,173) |
|
Revaluation of holdback receivable |
|
(83,580) |
|
- |
|
Amortization of property and equipment |
|
22,080 |
|
388,363 |
|
Amortization of intangible assets |
|
- |
|
2,505,697 |
|
Share-based compensation |
|
416,926 |
|
60,871 |
|
Finance expense, net |
|
76,222 |
|
2,158,865 |
|
Unrealized foreign exchange loss (gain) |
|
277,525 |
|
(364,289) |
Change in the following: |
|
|
|
|
|
Accounts receivable |
|
888,828 |
|
7,882,110 |
|
Inventories |
|
518,276 |
|
(382,600) |
|
Prepaid expenses |
|
(561,860) |
|
(946,185) |
|
Other assets |
|
- |
|
(6,175) |
|
Accounts payable and accrued liabilities |
|
(2,275,127) |
|
(4,073,366) |
|
Deferred revenue |
|
- |
|
(11,244) |
|
Other long-term liabilities |
|
- |
|
3,703 |
Interest received (paid), net |
|
131,949 |
|
(1,423,431) |
Income taxes paid |
|
(154,963) |
|
- |
Royalties paid |
|
(392,110) |
|
(395,146) |
Cash flows from (used in) operating activities |
|
319,351 |
|
(834,270) |
Investing activities: |
|
|
|
|
|
Proceeds from Apicore Sale Transaction |
|
65,234,555 |
|
- |
|
Acquisition of short-term investments, net |
|
(56,700,000) |
|
- |
|
Acquisition of property and equipment |
|
(95,137) |
|
(356,893) |
|
Acquisition of Class E common shares of Apicore |
|
- |
|
(935,595) |
Cash flows from (used in) investing activities |
|
8,439,418 |
|
(1,292,488) |
Financing activities: |
|
|
|
|
|
Exercise of stock options |
|
194,386 |
|
130,148 |
|
Exercise of Apicore stock options |
|
- |
|
122,471 |
|
Exercise of warrants |
|
- |
|
11,000 |
|
Repayment of long-term debt |
|
- |
|
(12,655,040) |
|
Decrease in cash in escrow |
|
- |
|
12,809,072 |
|
Finance lease payments |
|
- |
|
(40,178) |
|
Repayments of short-term borrowings |
|
- |
|
(5,717) |
Cash flows from financing activities |
|
194,386 |
|
371,756 |
Foreign exchange gain (loss) on cash held in foreign currency |
|
178,615 |
|
(3,140) |
Increase (decrease) in cash |
|
9,131,770 |
|
(1,758,142) |
Cash and cash equivalents, beginning of period |
|
5,260,480 |
|
12,266,177 |
Cash and cash equivalents, end of period |
$ |
14,392,250 |
$ |
10,508,035 |
View
original content:http://www.prnewswire.com/news-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2018-300653863.html
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2018/23/c7417.html
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 17:30e 23-MAY-18
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Apr 2023 to Apr 2024